ISCHEMIA MODIFIED ALBUMIN (IMA): A NOVEL BIOMARKER FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Volume 46, Issue 1, June 2023, Page 473-481 PDF (1.21 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2023.301186 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Aula Saker Abo Saleh  1; Bassem Marouf2; Afraa Zrieki3
| ||||
| 1Biochemistry and Microbiology Department, Faculty of Pharmacy, Tishreen University, Lattakia, Syria | ||||
| 2Internal Medicine Department, Faculty of Medicine, Tishreen University, Lattakia, Syria | ||||
| 3Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Tishreen University, Lattakia, Syria | ||||
| Abstract | ||||
| Due to the high mortality rate related to Acute Coronary Syndrome (ACS), early detection is critical. In the emergency room, ischemia modified albumin (IMA) has been proposed as a helpful indicator for the diagnosis of ACS. In this study, we aimed to investigate the role of IMA for its potential in the early diagnosis of ACS in patients experiencing sudden and severe chest pain, and the influence of some variables (gender, age, hypertension, diabetes, hypertriglyceridemia, hypercholesterolemia and smoking) on its level in ACS patients. A total of 127 patients with acute chest pain were included in the study. Patients were divided into three groups: those with acute myocardial infarction (N=45), unstable angina (N=52), and non-ischemic chest pain (NICP) (N=30). Patients with ACS had a higher level of IMA compared to those with NICP. To achieve the best sensitivity (86.5%) and specificity (76.7%), the cutoff for IMA was determined to be 71.3 u/ml. Based on our results, IMA is a sensitive marker for the early diagnosis of ACS in patients presenting with symptoms of acute chest pain. | ||||
| Keywords | ||||
| Ischemia modified albumin; unstable angina; myocardial infarction; Acute chest pain | ||||
|
Statistics Article View: 165 PDF Download: 143 |
||||
